Notifications
Clear all
Bladder Cancer
2
Posts
2
Users
0
Reactions
285
Views
Aug 22, 2023 11:37 am
1 Reply
Jan 04, 2024 3:49 pm
Transitional cell carcinoma (TCC), also known as urothelial carcinoma, is the most common type of bladder cancer. It originates in the urothelial cells lining the inside of the bladder. The term "transitional" is used because these cells can change shape and stretch as the bladder fills with urine. Transitional cell carcinoma can also develop in other parts of the urinary tract, such as the ureters and urethra.
Here are some key features of transitional cell carcinoma (TCC) of the bladder:
-
Origin:
- TCC arises from the transitional epithelium, which is a type of tissue lining the bladder. This tissue is also known as urothelium.
-
Prevalence:
- Transitional cell carcinoma is the most common type of bladder cancer, accounting for the majority of cases. It can also occur in other parts of the urinary tract.
-
Risk Factors:
- Several risk factors are associated with the development of transitional cell carcinoma, including cigarette smoking, exposure to certain industrial chemicals, older age, male gender (though it also affects females), and a history of chronic bladder inflammation or infection.
-
Presentation:
- Patients with transitional cell carcinoma may present with symptoms such as blood in the urine (hematuria), changes in urinary habits, pain during urination, and pelvic pain. However, early-stage bladder cancer may be asymptomatic.
-
Diagnosis:
- Diagnosis often involves imaging studies, such as cystoscopy and imaging of the urinary tract, to visualize the bladder and identify any abnormal growths or tumors. Biopsy samples may be taken during cystoscopy for histological examination.
-
Staging:
- Staging is essential to determine the extent of the cancer and guide treatment decisions. The TNM staging system (tumor size, lymph node involvement, and metastasis) is commonly used for bladder cancer staging.
-
Treatment:
- Treatment options for transitional cell carcinoma of the bladder depend on the stage and grade of the cancer. Treatment may include transurethral resection of the bladder tumor (TURBT), intravesical therapy, radical cystectomy (removal of the bladder), chemotherapy, and immunotherapy.
-
Prognosis:
- The prognosis for transitional cell carcinoma varies depending on the stage at diagnosis. Early-stage cancers confined to the urothelium have a better prognosis than invasive cancers that have spread into the muscular layers of the bladder or beyond.
Management of transitional cell carcinoma often involves a multidisciplinary approach with input from urologists, medical oncologists, and other healthcare professionals. Regular follow-up and monitoring are important for detecting recurrences and managing the long-term outcomes of bladder cancer.
